Investor Presentation Q1-Q3 2020

31 Investor presentation First nine months of 2020 Novo Nordisk® Novo Nordisk's core capabilities provide a competitive advantage to continue to defeat diabetes Engineering, formulating, developing and delivering protein-based treatments L Efficient large-scale production of proteins الله Global commercial reach and leader in chronic disease care |.000 ५ Deep disease understanding 0 Today: Oral solutions to differentiate from competition Tomorrow: Expand oral platforms and transformational medicines via Novo Nordisk stem cell platform balo Today: The world's largest producer of insulin and GLP-1 Tomorrow: Expand capacity by completion of the US diabetes API facility and continued efficiency gains Today: Global reach and OzempicⓇ was the fastest blockbuster in diabetes Tomorrow: Continued rollout of injectable diabetes portfolio and launch of RybelsusⓇ D Today: Provide value and outcomes beyond HbA1c for diabetes Tomorrow: Normalise living with diabetes supported by digital solutions API: Active pharmaceutical ingredient

View entire presentation